Spartalizumab
- Generic Name
- Spartalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1935694-88-4
- Unique Ingredient Identifier
- QOG25L6Z8Z
- Background
Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT05201066
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Uni of Massachusetts Medical Center, Worcester, Massachusetts, United States
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
- Conditions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 90
- Registration Number
- NCT05135845
- Locations
- 🇫🇷
Centre François Leclerc, Dijon, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Universitaire du Cancer, Toulouse, France
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 184
- Registration Number
- NCT04802876
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
🇪🇸Hospital Virgen del RocÃo, Sevilla, Spain
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT04323436
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸Massachusetts General Hospital Liver and Kidney TX, Boston, Massachusetts, United States
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04310397
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT04294160
- Locations
- 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute SC, Nashville, Tennessee, United States
Study of Select Combinations in Adults With Myelofibrosis
- First Posted Date
- 2020-02-25
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04283526
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
- Conditions
- Interventions
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT04261439
- Locations
- 🇺🇸
City of Hope National Medical, Duarte, California, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇨🇳Novartis Investigative Site, Taipei, Taiwan
Ribociclib and Spartalizumab in R/M HNSCC
- Conditions
- Interventions
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT04213404
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 14
- Registration Number
- NCT04028245
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.